Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Pentamidine Plus Oral Miltefosine for Bolivian Mucosal Leishmaniasis
NCT06550609Phase 2Recruiting
- Sponsor
- Fundación Nacional de Dermatología
- Start
- Feb 2025
- Primary completion
- Nov 2027
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of miltefosine, pentamidine in mucosal leishmaniasis (ML), sponsored by Fundación Nacional de Dermatología. Started Feb 2025; status: recruiting.
02
Drugs
miltefosinepentamidine
03
Conditions
mucosal leishmaniasis (ML)
Beyond the preview
Go deeper on NCT06550609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06550609.